Non-bacterial infections in allogeneic non-myeloablative stem cell transplant recipients

Transpl Infect Dis. 2007 Mar;9(1):3-10. doi: 10.1111/j.1399-3062.2006.00172.x.

Abstract

Data on non-bacterial infections during allogeneic non-myeloablative hematopoietic stem cell transplantation (HSCT) are widely different. We evaluated data on 48 consecutive patients who received a conditioning regimen with fludarabine and cyclophosphamide (73%) or fludarabine and total body irradiation (27%) and then underwent allogeneic non-myeloablative HSCT. Cytomegalovirus (CMV) infection was common and occurred in 48% of patients; 3 patients developed CMV disease, and all survived. CMV reactivation was found to be common with both conditioning regimens in our patient population. Invasive aspergillosis occurred in 4 patients (8%) and 3 died. Other serious non-bacterial infections were uncommon. Review of the available literature on non-myeloablative HSCT suggests that the frequency and type of opportunistic infections vary considerably.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Academies and Institutes
  • Antineoplastic Agents / administration & dosage
  • Aspergillosis / epidemiology*
  • Aspergillosis / etiology*
  • Cyclophosphamide / administration & dosage
  • Cytomegalovirus Infections / epidemiology*
  • Cytomegalovirus Infections / etiology*
  • Drug Therapy, Combination
  • Female
  • Hematopoietic Stem Cell Transplantation / adverse effects*
  • Humans
  • Immunosuppressive Agents / administration & dosage
  • Male
  • Michigan / epidemiology
  • Middle Aged
  • Myeloablative Agonists / administration & dosage
  • Neoplasms / therapy
  • Opportunistic Infections / epidemiology*
  • Opportunistic Infections / etiology*
  • Retrospective Studies
  • Review Literature as Topic
  • Transplantation Conditioning / adverse effects*
  • Vidarabine / administration & dosage
  • Vidarabine / analogs & derivatives
  • Whole-Body Irradiation

Substances

  • Antineoplastic Agents
  • Immunosuppressive Agents
  • Myeloablative Agonists
  • Cyclophosphamide
  • Vidarabine
  • fludarabine